Annual Report of a Foreign Private Issuer — Form 20-F Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 20-F Annual Report HTML 928K
3: EX-99.11 Code of Conduct HTML 165K
4: EX-99.12(A) Miscellaneous Exhibit HTML 11K
5: EX-99.12(B) Miscellaneous Exhibit HTML 11K
6: EX-99.13(A) Miscellaneous Exhibit HTML 6K
7: EX-99.13(B) Miscellaneous Exhibit HTML 6K
2: EX-99.8 List of Subsidiaries HTML 4K
I, Paul Averback, President and CEO
of Nymox Pharmaceutical Corporation, certify that:
1.
I have
reviewed this annual report on Form 20-F of Nymox Pharmaceutical Corporation;
2.
Based
on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3.
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the company as of, and for,
the periods presented in this report;
4.
The company’s other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a – 15(e) and 15d – 15(e)) for the company and we
have:
a)
designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision,
to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which
this report is being prepared;
b)
evaluated
the effectiveness of the company’s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosures and procedures, as of the end of the
period covered by this report based on such evaluation; and
c)
disclosed
in this report any change in the company’s internal control over
financial reporting that occurred during the period covered by the
annual report that has materially affected, or is reasonably likely
to materially affect, the company’s internal control over
financial reporting; and
5.
The
company’s other certifying officer(s) and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
company’s auditors and the audit committee of company’s board of
directors (or persons performing the equivalent function):
a)
All
significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably
likely to adversely affect the company’s ability to record,
process, summarize and report financial information; and
b)
Any
fraud, whether or not material, that involves management or other employees
who have a significant role in the company’s internal control
over financial reporting.
